Opportunity ID: 282697

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-FD-16-018
Funding Opportunity Title: Evaluation of Aberrant Observations and Their Impact on Bioequivalence Assessment (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Consumer Protection
Food and Nutrition
Health
Category Explanation:
Expected Number of Awards: 3
Assistance Listings: 93.103 — Food and Drug Administration_Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Apr 01, 2016
Last Updated Date:
Original Closing Date for Applications: Jun 03, 2016
Current Closing Date for Applications: Jun 03, 2016
Archive Date: Jul 03, 2016
Estimated Total Program Funding: $600,000
Award Ceiling: $200,000
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Small businesses
State governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Independent school districts
Others (see text field entitled “Additional Information on Eligibility” for clarification)
County governments
Public housing authorities/Indian housing authorities
Special district governments
For profit organizations other than small businesses
Private institutions of higher education
Native American tribal governments (Federally recognized)
Additional Information on Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the HHS Grants Policy Statement, are allowed.

Additional Information

Agency Name: Food and Drug Administration
Description: Aberrant observations in a bioequivalence study with pharmacokinetic endpoints may impact the estimation of residual variability, within-subject variability of the test and reference products, and potentially the bioequivalence conclusion. The purpose of this study is to evaluate and compare different quantitative methods for their capability in defining aberrant observations in bioequivalence studies with different study design features. Study results will advance regulatory science by improving the detection and understanding of aberrant observations and may help generic companies to evaluate the quality and in vivo performance of their proposed products.
Link to Additional Information: Full Announcement of RFA-FD-16-018
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Eric Bozoian

Grants Management Specialist

Phone 2404027623
Email:eric.bozoian@fda.hhs.gov

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: Eric Bozoian
Grants Management Specialist
Phone 2404027623
Email: eric.bozoian@fda.hhs.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
93.103 PKG00222285 Apr 04, 2016 Jun 03, 2016 View

Package 1

Mandatory forms

282697 RR_SF424_2_0-2.0.pdf

282697 PHS398_CoverPageSupplement_3_0-3.0.pdf

282697 RR_OtherProjectInfo_1_3-1.3.pdf

282697 PerformanceSite_2_0-2.0.pdf

282697 RR_KeyPersonExpanded_2_0-2.0.pdf

282697 RR_Budget_1_3-1.3.pdf

282697 PHS398_ResearchPlan_3_0-3.0.pdf

Optional forms

282697 RR_SubawardBudget30_1_3-1.3.pdf

282697 PHS_Inclusion_Enrollment_Report-1.0.pdf

282697 PHS_AssignmentRequestForm-1.0.pdf

2025-07-09T11:39:49-05:00

Share This Post, Choose Your Platform!

About the Author: